SCHEMBL17674604

SCHEMBL17674604

CC1c2ccccc2CCN1C(=O)Nc1ccc(Cl)cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAS1R3 Q7RTX0 3/20 0.63
▸ TAS1R1 Q7RTX1 3/20 0.63
▸ TAS1R2 Q8TE23 3/20 0.63
▸ DRD1 P21728 2/20 0.54
▸ GAA P10253 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ MAPT P10636 2/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ POLB P06746 2/20 0.47
▸ RECQL P46063 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ LIPE Q05469 1/20 0.47
▸ PPARG P37231 1/20 0.46
▸ PPARD Q03181 1/20 0.46
▸ PPARA Q07869 1/20 0.46
▸ THRB P10828 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17674644 0.83 DRD1 (0.61) TAS1R3TAS1R1TAS1R2DRD1GAA
SCHEMBL17674643 0.82 DRD1 (0.52) TAS1R3TAS1R1TAS1R2DRD1GAA
SCHEMBL17674616 0.81 DRD1 (0.67) TAS1R3TAS1R1TAS1R2DRD1GAA
SCHEMBL17674575 0.81 DRD1 (0.67) TAS1R3TAS1R1TAS1R2DRD1GAA
SCHEMBL17674681 0.81 DRD1 (0.67) TAS1R3TAS1R1TAS1R2DRD1GAA
SCHEMBL25206140 0.81 DRD1 (0.55) DRD1GAAMAPTMEN1KMT2A
SCHEMBL30446366 0.81 DRD1 (0.55) DRD1GAAMAPTMEN1KMT2A
SCHEMBL17674734 0.80 SMN1; SMN2 (0.61) DRD1MEN1KMT2APOLBNPC1
SCHEMBL17674641 0.79 DRD1 (0.49) TAS1R3TAS1R1TAS1R2DRD1MAPT
SCHEMBL17674635 0.79 TRPM8 (0.63) TAS1R3TAS1R1DRD1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3204359-B1 TETRAHYDROISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2020-07-01 — — EP disclosed
US-10105359-B2 Tetrahydroisoquinoline derivatives UCB BIOPHARMA SPRL (BE) 2018-10-23 — — US disclosed
US-20170304292-A1 Tetrahydroisoquinoline Derivatives UCB BIOPHARMA SPRL (BE) 2017-10-26 — — US disclosed
EP-3204359-A1 TETRAHYDROISOQUINOLINE DERIVATIVES UCB Biopharma SPRL (BE) 2017-08-16 — — EP disclosed
WO-2016055479-A1 TETRAHYDROISOQUINOLINE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2016-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304292-A1 Tetrahydroisoquinoline Derivatives OPRD1, ADRA1D, GPR52 TAS1R3 1277/4885TAS1R1 750/4885TAS1R2 941/4885
US-10105359-B2 Tetrahydroisoquinoline derivatives OPRD1, ADRA1D, GPR52 TAS1R3 1277/4885TAS1R1 750/4885TAS1R2 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback